IN8bio Inc (NASDAQ:INAB) has a beta value of 0.18 and has seen 0.7 million shares traded in the recent trading session. The company, currently valued at $14.00M, closed the recent trade at $0.17 per share which meant it lost -$0.03 on the day or -12.14% during that session. The INAB stock price is -923.53% off its 52-week high price of $1.74 and -11.76% below the 52-week low of $0.19. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.84 million shares traded. The 3-month trading volume is 5.43 million shares.
The consensus among analysts is that IN8bio Inc (INAB) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.07.
IN8bio Inc (NASDAQ:INAB) trade information
Sporting -12.14% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the INAB stock price touched $0.17 or saw a rise of 26.09%. Year-to-date, IN8bio Inc shares have moved -33.01%, while the 5-day performance has seen it change -24.40%. Over the past 30 days, the shares of IN8bio Inc (NASDAQ:INAB) have changed -35.97%. Short interest in the company has seen 1.67 million shares shorted with days to cover at 0.67.
IN8bio Inc (INAB) estimates and forecasts
The company’s shares have lost -39.54% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.22% over the past 5 years. Earnings growth for 2025 is a modest 63.45% while over the next 5 years, the company’s earnings are expected to increase by 23.82%.
INAB Dividends
IN8bio Inc is expected to release its next earnings report on 2025-Mar-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
IN8bio Inc (NASDAQ:INAB)’s Major holders
Insiders own 5.09% of the company shares, while shares held by institutions stand at 36.96% with a share float percentage of 38.94%. Investors are also buoyed by the number of investors in a company, with IN8bio Inc having a total of 28.0 institutions that hold shares in the company. The top two institutional holders are AIGH CAPITAL MANAGEMENT LLC with over 2.13 million shares worth more than $1.8 million. As of 2024-06-30, AIGH CAPITAL MANAGEMENT LLC held 4.7157% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 1.42 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.21 million and represent 3.2892% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Jan 31, 2025 , the former fund manager holds about 2.57% shares in the company for having 2.09 shares of worth $0.35 million while later fund manager owns 952.49 shares of worth $0.16 million as of Dec 31, 2024 , which makes it owner of about 1.17% of company’s outstanding stock.
